Background: Hemoglobin-based oxygen carriers can cause profound interferences in many analytical procedures. We determined the mechanism of interference in the assay of alkaline phosphatase activity and identified approaches that might be used to correct for this interference. Methods: Interference of a polymerized hemoglobin blood substitute with the assay of alkaline phosphatase was examined with a Hitachi 917 analyzer and ultraviolet-visible spectrophotometry. Results: Hemoglobin-based oxygen carrier solutions had substantial absorbance at 415 nm, the wavelength of analysis used to measure the formation of 4-nitrophenol. In addition to offsetting the initial absorbance at the analytical wavelength, polymerized hemoglobin gave rise to a strong negative interference plot because of alkali denaturation of the substitute. The same interference mechanism was also observed for native hemoglobin (hemolysate), indicating that the interference was not derived from the polymerization process. The interference can be corrected by implementing a ratecorrection procedure, or the interference can be avoided by measurement at 450 nm. Conclusions: The interference of polymerized hemoglobin in the alkaline phosphatase assay is a result of an absorbance offset caused by alkali denaturation of hemoglobin. The interference can be corrected or avoided by modifying the calculation or the analytical wave-
Oxygen carrier solutions, or blood substitutes, offer advantages over the use of erythrocytes in transfusion medicine (1 ) . These materials are acellular and remain a component of the plasma or serum, and may introduce interferences in laboratory tests (2, 3 ) . Hemoglobin-based oxygen carrier (HBOC) 3 solutions have an appearance similar to that of a standard hemolysate, and their presence in patient specimens might be expected to present a problem similar to that of a hemolyzed sample. Because of its broad absorbance spectrum, hemoglobin can interfere with spectroscopic measurements. Depending on the degree of hemolysis, the test may either be cancelled or be flagged with a comment code indicating that the reported result may be inaccurate because of hemolysis. With the use of HBOC solutions in transfusion medicine, the concentrations of interfering material may also be considerably greater than those encountered with typical hemolyzed samples.
Although there are reports on interferences caused by HBOC (4 -6 ) , little is known about the mechanisms of interference. It may be simplistically assumed that the interferences are purely spectral in nature because of the broad absorbance spectrum of polymerized hemoglobin. However, in internal studies we have noted a wide variability in interference plots seen with different analytes and different analyzers, which indicates that it is likely other factors are involved. Understanding the mechanism of HBOC interference will assist both manufacturers and laboratorians, and offer possibilities to correct the interference.
We performed a variety of spectroscopic studies to elucidate the mechanism of interference caused by HBOCs in a commonly used enzymatic test method for alkaline phosphatase. The studies confirmed that the broad background absorbance spectrum imposed by polymerized hemoglobin is not the only factor involved in the generation of interference. We present two strategies to render the method interference free, based on an understanding of the mechanism involved. These studies may also serve as a model for the investigation and correction of blood-substitute interferences in other clinical chemistry test methods.
Materials and Methods
Reagents for the alkaline phosphatase method on the Hitachi 917 clinical chemistry analyzer were obtained from the manufacturer (Roche/BMC). Both the R1 buffer solution and the R2 buffer/substrate solution contain Ն0.93 mol/L 2-amino-2-methyl-1-propanol (AMP), pH 10.5, and Ն1.04 mmol/L magnesium-l-aspartate as reactive ingredients, and hydrochloric acid and zinc sulfate heptahydrate as nonreactive ingredients. The R2 buffer/substrate reagent also contains Ն97.9 mmol/L 4-nitrophenylphosphate.
A commercially developed polymerized hemoglobin solution was used for all interference studies (PolyHeme; Northfield Laboratories). This blood substitute consists of native tetrameric human hemoglobin polymerized using glutaraldehyde and modified by pyridoxal phosphate to optimize the P50 value. The commercial solution has a hemoglobin concentration of 100 g/L and is essentially free of all unreacted tetramer. The latter claim was verified by gel filtration chromatography fractionation using a 2.5 ϫ 50 cm column packed with Sephadex G-200 gel (Sigma) and elution with 0.1 mol/L phosphate buffer, pH 7.4. The molecular weight distribution of the materials was determined using a molecular weight marker kit (MW-GF-1000 kit; Sigma) with protein markers spanning the range M r 29 000 -2 000 000. Native hemoglobin was obtained in-house from a standard hemolysate. Refrigerated serum specimens were used as the source of alkaline phosphatase.
Samples for the interference studies were prepared by adding blood substitute and saline to serum. Three series of solutions were prepared with different alkaline phosphatase activity (low, 60 U/L; normal, 100 U/L; high, 160 U/L). The HBOC concentration in each series was 0 -50 g/L. The interference samples were analyzed for alkaline phosphatase on the Hitachi 917 in standard mode. Test result and absorbance vs time data were accessed via the software module of the analyzer. Spectrophotometric studies were also performed using a Lambda 3B ultraviolet (UV)-visible spectrophotometer (Perkin-Elmer) with selected interference study samples, in either fixed wavelength or scan mode. Data from all studies were imported into a statistical software program for further analysis.
Results and Discussion
The Hitachi 917 alkaline phosphatase method uses an AMP buffer and is specifically designed to provide reproducible final reaction conditions over long periods of time. The principle of the method involves the hydrolysis of 4-nitrophenylphosphate in the presence of magnesium ions by phosphatases
The rate of formation of the yellow-colored 4-nitrophenol product is directly proportional to the serum alkaline phosphatase (ALKP) activity in U/L. The method involves bichromatic analysis using a primary wavelength of 415 nm and a secondary wavelength of 660 nm, with the "primary Ϫ secondary" difference absorbance used in actual computations. References to "415 nm" on the Hitachi 917 in this report are meant to refer to the difference absorbance value. Initially, 4.4 L of sample (serum) and 180 L of buffer solution are combined. After an incubation phase, 36 L of substrate solution is added followed by a lag phase (37°C). Thereafter, the rate of change is calculated from absorbance readings taken over a period of 3 min (7 ).
As a first step, we examined the molecular weight distribution and UV-visible absorbance spectrum of polymerized hemoglobin. Absorbance measurements (280 nm and 415 nm) of the fractions obtained from gel-filtration chromatography demonstrated that the blood substitute contains a distribution of hemoglobin polymers with molecular weights of 100 000 -600 000. No detectable absorbance was found in the fractions where native hemoglobin elutes (M r ϳ65 000). The glutaraldehyde crosslinking produces a spectrum that is still essentially identical to native hemoglobin, with oxyhemoglobin peaks in the 540 -580 nm region and a large Soret band near 410 nm (Fig. 1 ). This latter band, however, overlaps the 4-nitrophenol peak absorbance at the analytical wavelength of 415 nm.
It might be expected that because the alkaline phosphatase assay is a kinetic rate method, the presence of HBOC would offset the absorbance readings but not necessarily influence the rate of product formation measured at 415 nm. However, interference plots for alkaline phosphatase (Fig. 2) show that as the concentration of HBOC in the serum specimen increases, there is a linear decrease in the Hitachi 917 test result. This observation is indicative of an additional mechanism that attenuates the rate of increase in the measured absorbance at 415 nm. A test result less than the limit of detection is obtained when there is no alkaline phosphatase activity present, regardless of HBOC concentration. The interference plot is also consistent with the claim that the Hitachi 917 alkaline phosphatase assay exhibits significant negative interference from hemoglobin at a hemolysis index (
The test result data from the interference plots ( Fig. 2 ) were evaluated using a statistical software package (Statmost, Ver.2.5; DataMost Corp.). Multiple regression analysis failed to find a significant coefficient for the crossterm (8 ) , indicating that there is no interaction between enzyme and blood substitute. The parallel interference plots in Fig. 2 also support this conclusion, demonstrating that the magnitude of the interference is a function only of the HBOC concentration and is independent of the activity of alkaline phosphatase. The interference from the blood substitute is approximately constant at Ϫ50 U/L alkaline phosphatase per 10 g/L HBOC, regardless of the activity of alkaline phosphatase. Furthermore, Lineweaver-Burk plots (not shown) constructed from studies performed on the spectrophotometer did not indicate either a purely competitive or noncompetitive enzyme inhibition model. Taken together, these observations are consistent with a mechanism in which the blood substitute acts as an independent contributor of interference in this method.
We sought to further elucidate the mechanism by examining the absorbance data accessible through the software module of the Hitachi 917. The alkaline phosphatase assay consists of a total of 34 measurement points, each spaced by 20-s intervals. The analyzer software multiplies the absorbance scale by a factor of 10 000 for greater resolution (see Table 1 and Fig. 3 ). For an ordinary sample, the incubation interval (first 16 measurement points) of sample with buffer (R1) is relatively flat with absorbance values close to zero. Addition of substrate solution (R2) at point 17 shifts the reaction plot up because of absorbance of substrate (in excess) at 415 nm. A positive slope is observed thereafter because of enzymatic formation of product, and the rate of change of absorbance measured between points 25 and 34 is used to calculate the enzyme activity. For a sample containing HBOC, the absorbance readings are offset because of the strong absorbance of the blood substitute at 415 nm, and a negative slope is observed during the incubation interval. After addition of substrate at point 17, the sample with blood substitute exhibits an apparent decreased rate of product formation, as indicated by a lower slope during the measurement interval.
As mentioned earlier, absorbance values used for activity calculations by the Hitachi 917 software are the difference between the primary wavelength absorbance reading (415 nm) and the secondary wavelength absorbance reading (660 nm). As observed at 415 nm, the absorbance also increases at 660 nm in proportion to the amount of HBOC present. However, these increases are negligible (Ͻ1%) compared with the increases observed at 415 nm. Furthermore, it was demonstrated (see later in text) that there is zero drift at 660 nm in the presence of HBOC. We have used the difference values in our calculations and plots, although the results are identical when only the primary wavelength is used. The interference is independent of changes occurring at the secondary wavelength.
The effect of blood substitute on the Hitachi 917 measurement point data was examined in closer detail using a serum specimen with an alkaline phosphatase activity of 500 U/L. The decrease in the apparent rate of product formation observed during the measurement interval (Fig. 3A, points 25-34) is roughly a constant function of the HBOC concentration, consistent with previous observations. The decline in absorbance values observed during the incubation interval (Fig. 3B, points  1-16 ) is also a relatively constant function of the HBOC Fig. 1 . Absorbance spectra of HBOC (Ⅺ) and product of alkaline phosphatase assay (4-nitrophenol; E). concentration. The absorbance values for the sample with no blood substitute are relatively stable, whereas increasing amounts of HBOC produce an increasingly negative slope during this interval. The same effect is observed both with and without the presence of serum/alkaline phosphatase. In particular, the negative slope does not reach a plateau at the end of the incubation interval, but continues into the subsequent measurement interval after addition of substrate. This was readily observed in specimens containing blood substitute but no alkaline phosphatase activity.
We examined the possibility that the decreasing absorbance of the polymerized hemoglobin in the buffer reagent is attributable to a pH effect. To test this hypothesis, studies were performed with a different buffer than the Roche AMP buffer reagent. A constant amount of HBOC was added to a series of phosphate buffer solutions spanning the pH range 4 -11. After addition, the absorbance at 415 nm was measured with the spectrophotometer for a 10-min interval. The blood substitute is relatively stable in the pH range 5-10 but exhibits a marked negative shift in absorbance at both extremes of pH (pH 4 and 11). In particular, there is a rapid reorganization or denaturation that occurs above pH 10, consistent with the negative drift in absorbance on the Hitachi 917 analyzer, which uses an AMP buffer with a pH of 10.5 (Fig. 4) . Of interest is our observation (in separate studies) that the alkaline phosphatase/AMP assay used on the CX-7 (Beckman) also has a negative interference plot with this blood substitute, but the interference is less pronounced than that observed in the Hitachi 917 method. Because the CX-7 method is essentially identical to the Hitachi 917 method (same reagents and same wavelength) but uses an AMP buffer with a lower pH of 10.3, it is possible that the reduced interference on this analyzer is attributable to a reduced rate of denaturation at the lower pH.
Overall, these results indicate that the interference caused by the declining absorbance of HBOC at 415 nm is attributable to a pH effect rather than a chemical interaction between blood substitute and components of the buffer solution. Furthermore, interference studies done with native hemoglobin gave results identical to those with the blood substitute, indicating that the observed interferences are mainly attributable to the hemoglobin units in the blood substitute and not to any special properties that may have been introduced as a result of the polymerization process.
To correct for the interference caused by the presence of blood substitute, a rate-correction procedure was investigated. The Hitachi 917 alkaline phosphatase activity (C) result is calculated by the formula C ϭ k⌬A [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , where k is a constant and ⌬A is the change in absorbance per minute (rate) observed during the measurement interval (measurement points 25-34, which represent a 3-min time period). If it is assumed that the decrease in ⌬A 25-34 seen when HBOC is present is because of an offset caused by the simultaneous denaturation of hemoglobin, it becomes apparent that the negative rate observed during the incubation interval could be applied as a correction. However, it was observed that this rate gradually changes over time (Fig. 3B) . Therefore, to approximate the rate of alkali denaturation during the measurement interval, we examined the difference between the fourth (measurement points 10 -13) and fifth (points 13-16) minutes of the incubation interval and calculated:
⌬A corrected ϭ ⌬A 25-34 Ϫ ⌬A 13-16 ϩ ͓⌬A 10-13 Ϫ ⌬A 13-16 ͔ ϭ ⌬A 25-34 Ϫ 2⌬A 13-16 ϩ ⌬A [10] [11] [12] [13] Use of C ϭ k⌬A corrected then returns a corrected value for alkaline phosphatase. The results are presented in Table 1 . Use of this algorithm significantly improves the reported values, allowing the method to return results within 15% of the expected value up to a HBOC concentration of 30 g/L. The rate correction method fails at higher concentrations of blood substitute because of poor photodiode detector performance when transmitted light is low (excessive absorbance). No effect is expected from the additional buffering capacity from high concentrations of hemoglobin because the concentration of AMP buffer is always several orders of magnitude higher.
The use of an alternate wavelength at which drift attributable to alkali denaturation of hemoglobin might be negligible was also considered as a possible strategy to avoid interference from the blood substitute. To identify a suitable wavelength, HBOC was added to AMP buffer and the absorbance spectrum was measured on the spectrophotometer at t ϭ 0 and t ϭ 10 min. The difference of these two spectra is plotted in Fig. 4 . As expected, peaks characteristic of hemoglobin underwent a negative shift during the 10-min interval. Incidentally, we noted that drift at the secondary wavelength used in the Hitachi method, 660 nm, was close to zero. We found that use of the region near 320 (340) nm was prohibited by excessively strong absorbance from the enzyme substrate. We therefore selected 450 nm as a wavelength at which product absorbs (Fig. 1) but at which drift attributable to alkali denaturation should be close to zero. The wavelength 450 nm was selected instead of 440 nm because it is a wavelength that frequently is available in commercial chemistry analyzers.
The performance of the alkaline phosphatase method at 415 nm vs 450 nm is shown in Fig. 5 . The studies were performed on the spectrophotometer, using the Hitachi 917 reagents and allowing a 5-min incubation interval of serum in AMP buffer before addition of substrate. The activity of alkaline phosphatase was the same in all experiments (150 U/L). After the addition of substrate and allowing a 3-min lag phase, we found that the subsequent 4-min change in absorbance at 415 nm showed a large decrease with increasing HBOC concentrations, but that the absorbance at 450 nm was relatively stable (Fig. 5A) . The 4-min change in absorbance was chosen as the measured variable rather than the change in absorbance per minute to provide larger numbers and to improve the resolution in the comparison. When the data are presented in terms of the percentage difference in the 4-min absorbance change from that observed when no blood substitute is present (Fig. 5B) , the use of 450 nm as the analytical wavelength returns a result within 15% of the expected value and permits the method to be used up to a HBOC concentration of 50 g/L.
In this report, our intention was to identify and confirm the mechanism of interference of a polymerized hemoglobin blood substitute in an alkaline phosphatase method commonly used on clinical chemistry analyzers. An aliquot of blood substitute was added to 2 mL of the AMP buffer reagent, and the absorbance spectrum was obtained. A second spectrum was obtained 10 min later, and the difference was plotted. The plot indicates which wavelengths are stable and which wavelengths show a shift in absorbance over time.
The blood substitute we examined (PolyHeme) may be useful as a safe alternative to allogeneic red blood cells in transfusion medicine (9 ) , and would seem to be poised to gain market approval after the completion of current phase III clinical trials. This blood substitute is different from its predecessor (dissociable tetrameric hemoglobin) in having minimal toxicities of renal dysfunction and vasoconstriction. However, as an interferent it behaves remarkably similarly to native hemoglobin. This similarity is evident in both the UV-visible absorbance spectrum and in the interference mechanism observed in the alkaline phosphatase assay.
The mechanism of interference of polymerized hemoglobin in the alkaline phosphatase assay involves an alkali denaturation of hemoglobin, which causes a decreasing absorbance at 415 nm, which in turn decreases the apparent rate of product formation after the addition of substrate. The interference appears to depend solely on the concentration of blood substitute and not on an interaction with reagent components, causing a constant interference of approximately Ϫ50 U/L per 10 g/L HBOC. The phenomenon of alkali denaturation has in fact been exploited previously in the measurement of fetal hemoglobin (10, 11 ) , in which addition of sodium hydroxide is used to denature and ultimately remove all hemoglobin types except the alkali-resistant hemoglobin F.
The elucidation of the mechanism allowed us to formulate two strategies to extend the interference-free range of this method. The use of a rate-correction method (similar to that used in the creatinine/rate-blanked method) should permit the method to be useful up to a HBOC concentration of 30 g/L depending on the initial alkaline phosphatase activity. However, an even more promising approach may be to use 450 (or 440) nm as the analytical wavelength, which based on our initial studies would appear to be free from interference up to a HBOC concentration of 50 g/L.
In general, it is expected that the majority of blood substitute-containing specimens will have a concentration Ͻ50 g/L. In situations such as trauma where many units of HBOC might be transfused, the use of alternative wavelengths in the correction of test interferences is likely to be the preferred approach because it avoids the excessive absorbance values associated with the characteristic wavelengths of hemoglobin. In addition, because it was demonstrated that the magnitude of the interference is a function only of the concentration of blood substitute and is independent of the alkaline phosphatase activity, the proposed corrections should also be valid for increased values of alkaline phosphatase such as observed in the pediatric population.
It is clear from these studies that understanding the underlying mechanism can be an indispensable tool in the development of new or modified methods that have reduced interference from blood substitutes. In the case of the alkaline phosphatase method and probably other Experiments were performed on the UV-visible spectrophotometer using serum with added HBOC and Hitachi 917 reagents in the same proportions as used on the analyzer. The absorbance at both wavelengths was measured after a 5-min incubation interval and a 3-min lag phase after addition of R2 (also analogous to the time format used on the Hitachi 917). However, a 4-min total change in absorbance was used as the variable during the measurement interval to improve resolution because of the lowered absorbance values at 450 nm. At 450 nm, the 4-min change in absorbance is relatively stable, whereas at 415 nm, it decreases significantly with increasing HBOC concentrations (A; compare with Fig. 2 and Fig. 3A) . In terms of percentage bias (B), the 4-min change in absorbance is within 15% of that observed when no blood substitute is present, even up to a blood substitute concentration of 50 g/L.
methods, mechanisms other than the commonly cited, mere superimposition of a hemoglobin-like absorbance spectrum can be involved. Manufacturers of clinical chemistry analyzers will need to perform complete interference studies involving large amounts of data to document the performance of new or modified methods at all anticipated concentrations of both analyte and blood substitute. It is hoped that the results presented here will serve as a solid starting point for manufacturers in resolving the strong interference seen in the alkaline phosphatase method. The experiments described herein may also serve as a model for the investigation and resolution of blood substitute interferences in other tests.
The results presented herein should also be of great interest to manufacturers interested in improving the hemolysis index for the alkaline phosphatase method. Because the mechanism of interference is identical for both native and polymerized hemoglobin, the correction strategies presented will be applicable to efforts to increase the extent of hemolysis permitted (i.e., hemolysis index) for reporting of results. This would be a small but welcome improvement in the clinical laboratory, regardless of whether blood substitutes are in use.
